Chemed Co. (NYSE:CHE) has earned an average recommendation of “Hold” from the eight research firms that are presently covering the stock, MarketBeat.com reports. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $261.33.
A number of equities analysts have recently commented on CHE shares. ValuEngine lowered shares of Chemed from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Oppenheimer raised their price objective on shares of Chemed from $270.00 to $275.00 and gave the company an “outperform” rating in a research report on Friday, February 16th. Finally, Royal Bank of Canada restated a “hold” rating and issued a $258.00 price objective on shares of Chemed in a research report on Friday, February 16th.
Chemed (NYSE:CHE) traded up $8.10 during mid-day trading on Thursday, hitting $279.81. 113,834 shares of the stock were exchanged, compared to its average volume of 107,671. The company has a debt-to-equity ratio of 0.17, a current ratio of 0.91 and a quick ratio of 0.88. Chemed has a one year low of $178.44 and a one year high of $281.00. The company has a market capitalization of $4,522.01, a price-to-earnings ratio of 48.16 and a beta of 1.10.
Chemed (NYSE:CHE) last released its quarterly earnings data on Wednesday, February 14th. The company reported $2.32 EPS for the quarter, beating analysts’ consensus estimates of $2.27 by $0.05. Chemed had a net margin of 5.89% and a return on equity of 30.04%. The company had revenue of $428.35 million during the quarter, compared to analyst estimates of $423.83 million. During the same period last year, the business earned $2.10 earnings per share. Chemed’s revenue was up 6.2% compared to the same quarter last year.
Chemed announced that its Board of Directors has initiated a stock repurchase plan on Tuesday, March 6th that authorizes the company to buyback $150.00 million in shares. This buyback authorization authorizes the company to repurchase shares of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s board of directors believes its stock is undervalued.
The business also recently announced a quarterly dividend, which will be paid on Monday, March 19th. Shareholders of record on Monday, February 26th will be given a dividend of $0.28 per share. The ex-dividend date of this dividend is Friday, February 23rd. This represents a $1.12 annualized dividend and a yield of 0.40%. Chemed’s payout ratio is presently 19.28%.
In other Chemed news, insider Kevin J. Mcnamara sold 6,000 shares of Chemed stock in a transaction that occurred on Thursday, March 1st. The shares were sold at an average price of $258.00, for a total transaction of $1,548,000.00. Following the completion of the sale, the insider now directly owns 140,049 shares in the company, valued at $36,132,642. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Naomi C. Dallob sold 1,050 shares of Chemed stock in a transaction that occurred on Wednesday, February 21st. The shares were sold at an average price of $257.00, for a total transaction of $269,850.00. Following the sale, the vice president now owns 6,649 shares of the company’s stock, valued at $1,708,793. The disclosure for this sale can be found here. Insiders own 4.90% of the company’s stock.
A number of institutional investors have recently made changes to their positions in CHE. Raymond James Financial Services Advisors Inc. bought a new stake in Chemed during the third quarter valued at approximately $259,000. Crossmark Global Holdings Inc. bought a new stake in Chemed during the third quarter valued at approximately $418,000. IFP Advisors Inc lifted its position in Chemed by 1,504.5% during the third quarter. IFP Advisors Inc now owns 706 shares of the company’s stock valued at $143,000 after purchasing an additional 662 shares during the last quarter. Old Mutual Global Investors UK Ltd. lifted its position in Chemed by 173.5% during the third quarter. Old Mutual Global Investors UK Ltd. now owns 95,212 shares of the company’s stock valued at $19,237,000 after purchasing an additional 60,399 shares during the last quarter. Finally, Chicago Equity Partners LLC lifted its position in Chemed by 80.2% during the third quarter. Chicago Equity Partners LLC now owns 31,595 shares of the company’s stock valued at $6,384,000 after purchasing an additional 14,065 shares during the last quarter. Institutional investors and hedge funds own 93.69% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This article was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/03/18/brokerages-set-chemed-co-che-pt-at-261-33.html.
Chemed Company Profile
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.